| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2023 | Apr 14, 2023 | Jasper Therapeutics, Inc. | Director | Sell | 26.3 | -9,075 | -30.00% | ✗ | $13.5K |
| May 17, 2021 | May 18, 2021 | Vera Therapeutics, Inc. | Director | Buy | 100.0 | +790,555 | 36.14% | ✗ | $8.7M |
| Jun 16, 2020 | Jun 18, 2020 | Vaxcyte, Inc. | Director | Buy | 65.0 | +12,500 | 0.30% | ✗ | $200K |
| Dec 18, 2018 | Jan 18, 2019 | CRISPR Therapeutics AG | Director | Sell | 17.5 | -62,925 | -5.10% | ✗ | $1.9M |
| Dec 17, 2018 | Dec 19, 2018 | CRISPR Therapeutics AG | Director | Sell | 17.5 | -72,934 | -5.90% | ✗ | $2.2M |
| Jun 5, 2018 | Jun 7, 2018 | CRISPR Therapeutics AG | Director | Sell | 43.8 | -920 | -0.24% | ✗ | $11.5K |
| May 11, 2018 | May 15, 2018 | CRISPR Therapeutics AG | Director | Sell | 15.0 | -650,000 | -34.44% | ✗ | $35.4M |
| Jan 5, 2018 | Jan 11, 2018 | CRISPR Therapeutics AG | Director | Buy | 92.5 | +65,934 | 3.62% | ✗ | $1.5M |
| Jan 5, 2018 | Jan 9, 2018 | CRISPR Therapeutics AG | Director | Sell | 32.5 | -92,337 | -4.83% | ✓ | $2.5M |
| Jan 2, 2018 | Jan 4, 2018 | CRISPR Therapeutics AG | Director | Sell | 40.0 | -37,754 | -1.93% | ✓ | $1M |
| Aug 28, 2017 | Aug 30, 2017 | CRISPR Therapeutics AG | Director | Sell | 32.5 | -88,011 | -4.32% | ✓ | $1.7M |
| Aug 24, 2017 | Aug 28, 2017 | CRISPR Therapeutics AG | Director | Sell | 42.5 | -22,781 | -1.10% | ✓ | $442.4K |
| Aug 22, 2017 | Aug 24, 2017 | CRISPR Therapeutics AG | Director | Sell | 45.0 | -17,989 | -0.86% | ✓ | $333.3K |
| Aug 18, 2017 | Aug 22, 2017 | CRISPR Therapeutics AG | Director | Sell | 50.0 | -3,150 | -0.15% | ✓ | $58.3K |
| Aug 16, 2017 | Aug 18, 2017 | CRISPR Therapeutics AG | Director | Sell | 42.5 | -34,141 | -1.61% | ✓ | $650.7K |
| Aug 14, 2017 | Aug 16, 2017 | CRISPR Therapeutics AG | Director | Sell | 36.3 | -55,569 | -2.56% | ✓ | $1.1M |
| Aug 7, 2017 | Aug 9, 2017 | CRISPR Therapeutics AG | Director | Sell | 42.5 | -35,473 | -1.59% | ✓ | $660.9K |
| Aug 3, 2017 | Aug 7, 2017 | CRISPR Therapeutics AG | Director | Sell | 38.8 | -50,477 | -2.22% | ✓ | $899.2K |
| Jul 31, 2017 | Aug 2, 2017 | CRISPR Therapeutics AG | Director | Sell | 50.0 | -5,512 | -0.24% | ✓ | $96.5K |
| Jul 27, 2017 | Jul 31, 2017 | CRISPR Therapeutics AG | Director | Sell | 42.5 | -41,312 | -1.78% | ✓ | $728.1K |
| Jul 25, 2017 | Jul 27, 2017 | CRISPR Therapeutics AG | Director | Sell | 42.5 | -32,930 | -1.40% | ✓ | $579.5K |
| Jul 13, 2017 | Jul 17, 2017 | CRISPR Therapeutics AG | Director | Sell | 36.3 | -69,859 | -2.88% | ✓ | $1.2M |
| Jul 11, 2017 | Jul 13, 2017 | CRISPR Therapeutics AG | Director | Sell | 42.5 | -31,992 | -1.31% | ✓ | $529.9K |
| Jul 5, 2017 | Jul 7, 2017 | CRISPR Therapeutics AG | Director | Sell | 50.0 | -4,254 | -0.17% | ✓ | $69.2K |
| Jun 28, 2017 | Jun 30, 2017 | CRISPR Therapeutics AG | Director | Sell | 42.5 | -43,202 | -1.74% | ✓ | $730.1K |
| Jun 26, 2017 | Jun 28, 2017 | CRISPR Therapeutics AG | Director | Sell | 32.5 | -81,435 | -3.17% | ✓ | $1.4M |
| Jun 22, 2017 | Jun 26, 2017 | CRISPR Therapeutics AG | Director | Sell | 42.5 | -32,368 | -1.24% | ✓ | $525.3K |
| Oct 24, 2016 | Feb 10, 2017 | CRISPR Therapeutics AG | Director | Buy | 85.0 | +56,000 | 2.20% | ✗ | $784K |